We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Big Gains To Be Made From US-Exposed Stocks Like Diageo plc, AstraZeneca plc And SABMiller plc

Keen to make big gains from a rising US dollar? This Fool has some great stock picks including Diageo plc (LON:DGE), AstraZeneca plc (LON:DGE) and SABMiller plc (LON:SAB).

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Companies with international exposure face two main risks. The first is that the country in which they are trading goes into recession (or some kind of major downturn), and the second is currency fluctuations.

I want to look at three companies in the FTSE 100 that should actually benefit from a growing US economy, and a lift in the value of the US dollar.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

The case for more US growth

The United States has benefited from years and years of ‘cheap’ money from the Federal Reserve. Quantitative easing and a boom in the share market has seen a pick-up in growth that began tentatively in 2013 and has picked up pace in 2014. According to the second estimate released by the Bureau of Economic Analysis, the US economy grew at an annualised 3.9% in the third quarter of 2014 — that’s above trend. Consumer spending increased 2.2% in the third quarter. The services sector also expanded 1.2%.

This week we also learned that policy makers have been able to keep the US unemployment rate at 5.8%.

I have my doubts about the sustainability of this US recovery. Indeed history tells us that recoveries like the one we are witnessing right now are usually interrupted with another significant fall in industrial production, but the present reality is that the economy is growing again. Investors can take advantage of that as you’ll see below.

The mighty US dollar

Companies often have currency hedging policies in place to safeguard their offshore earnings. Obviously if the currency of the country the company is trading in falls dramatically, earnings will be negatively affected. Firms usually take out ‘insurance’ against this. What if the currency starts to appreciate though over the longer term? If this appreciation in the currency coincides with an overall pick-up in aggregate demand with the country, firms trading within that market can see their valuations start to rise.

Diageo

North America accounts for around 30% of Diageo’s (LSE: DGE) (NYSE: DEO.US) net sales, and around 45% of its operating profit. The beverage trader has had its setbacks (including disappointing sales for Smirnoff vodka), and it’s still recovering from a spending spree instigated by former CEO, Paul Walsh, but analysts accept that the medium-term outlook for Diageo is good. Specifically, City folk cite Diageo’s extensive product portfolio as a reason for it to perform soundly in America in 2015.

Africa is also a great source of revenue for the beverage maker. According to the African Development Bank, there will be 65 million more legal drinkers in Africa by 2023. Diageo’s already throwing more than £1 billion at this market.

SABMiller

North America accounts for around 12% of SABMiller’s (LSE: SAB) earnings before interest, tax and amortisation. The bottler will therefore benefit from further growth in the US in a similar way that Diageo with benefit from it — increasing market reach, combined with growing consumer demand.

In addition, international ratings agency Fitch also cites several reasons why SABMiller is now standing out from the pack. Fitch says the firm’s debt position has improved following the acquisition of Foster’s, and the company is also set to benefit further from its exposure to developing markets. Fitch also likes the look of SABMiller’s $500 million cost-cutting programme. If that wasn’t enough, the company’s tie-up with The Coca-Cola Company in Africa, Coca-Cola Beverages Africa, should deliver synergies for SABMiller making it quite attractive in 2015.

AstraZeneca

AstraZeneca (LSE: AZN) (NYSE: AZN.US) will not only benefit from further economic growth in the US and an appreciation of the US dollar, but it is also proactively, even if slowly, pushing further into this growing market. AstraZeneca’s latest results were encouraging: ‘Brilinta’ sales were up 78%, there was a strong launch of ‘Farxiga’, and it recorded ‘Symbicort’ growth of 26%.

In addition, just as SABMiller enjoys market share growth in Africa, AstraZeneca is benefiting from increased sales activity in China. The drugs makers recorded a growth injection of around 22% from China in its latest results.

The companies mentioned above all stand to gain in 2015 from a growing US economy, an appreciation in the greenback, and increased trading activity in emerging markets. No investment is guaranteed but these stocks are all worth a closer look for those seeking some growth next year.

David Taylor has no position in any shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian man making doubtful face at camera
Investing Articles

SpaceX stock has halved in weeks. Could it quickly double again?

What goes down doesn't necessarily come up. After its recent crash, this writer does see a possible way back for…

Read more »

Engineers in data centre using device, verifying firewall configurations. Teamworking IT professionals performing equipment vulnerability scans in server hub using tablet
Investing Articles

Meet the Legal & General ETF crushing the FTSE 100 index in 2026 

Ben McPoland highlights a thematic ETF that has beaten the FTSE 100 index by a wide margin recently. But is…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Here’s what £500 invested in Rolls-Royce shares a year ago is worth now

Christopher Ruane looks at how Rolls-Royce shares have outperformed the market over the past year -- and explains whether he…

Read more »

Investing Articles

Prediction: by August 2027 the BT share price and dividend could turn £9,999 into…

The BT share price has retreated in recent weeks. Now Harvey Jones checks out the FTSE 100 company's income and…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
US Stock

£3,846 invested in Micron stock now could be worth this much by summer 2027

Jon Smith makes a call on where he sees Micron stock potentially trading over the coming year and weighs this…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

Here’s why the Diageo share price is up 10.5% since 1 July

The Diageo share price has outperformed the FTSE 100 this month. But is this yet another false dawn for long-suffering…

Read more »

Warhammer World gathering
Investing Articles

My favourite FTSE 100 stock just got cheaper. Time to consider buying?

Paul Summers checks out the latest set of full-year numbers from this highly-profitable FTSE 100 stock. What's got investors spooked?

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

By mid-2027, £5,000 in this FTSE 250 stock could grow to £8,200, if analysts are right

FTSE 250 stock Raspberry Pi is up almost 50% over the last year. And analysts at Peel Hunt expect the…

Read more »